Experienced in Acute Megakaryoblastic Leukemia

Dr. Raajit K. Rampal

Oncology | Hematology
Memorial Hematology Lymphoma Group
1275 York Ave, 
New York, NY 
Offers Telehealth
Experienced in Acute Megakaryoblastic Leukemia
Memorial Hematology Lymphoma Group
1275 York Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Raajit Rampal is an Oncologist and a Hematologist in New York, New York. Dr. Rampal is rated as an Experienced provider by MediFind in the treatment of Acute Megakaryoblastic Leukemia. His top areas of expertise are Myeloproliferative Neoplasms (MPN), Myelofibrosis, Essential Thrombocythemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 168 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Acute Megakaryoblastic Leukemia.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

MEMORIAL HEMATOLOGY LYMPHOMA GROUP
1275 York Ave, New York, NY 10065
Other Locations
MEMORIAL HEMATOLOGY LYMPHOMA GROUP
530 E 74th St, New York, NY 10021

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: CPI-0610, Rituximab
Study Phase: Phase 1/Phase 2
Evaluation of Ruxolitinib And Thalidomide Combination as a Therapy for Patients With Myelofibrosis
Evaluation of Ruxolitinib And Thalidomide Combination as a Therapy for Patients With Myelofibrosis
Enrollment Status: Active_not_recruiting
Publish Date: March 04, 2025
Intervention Type: Drug
Study Drugs: Ruxolitinib, Thalidomide
Study Phase: Phase 2
A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Ruxolitinib, Enasidenib
Study Phase: Phase 2
Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)
Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)
Enrollment Status: Completed
Publish Date: September 12, 2019
Intervention Type: Drug
Study Phase: Phase 1
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Enrollment Status: Completed
Publish Date: April 30, 2019
Intervention Type: Drug
Study Phase: Phase 3
Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML
Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML
Enrollment Status: Completed
Publish Date: February 28, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Enrollment Status: Completed
Publish Date: January 11, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

168 Total Publications

Results from a US modified Delphi consensus to define disease progression and disease modification in polycythemia Vera.
Results from a US modified Delphi consensus to define disease progression and disease modification in polycythemia Vera.
Journal: Annals of hematology
Published: August 12, 2025
Similar Doctors
Advanced in Acute Megakaryoblastic Leukemia
Dr. Divaya Bhutani
Hematology | Oncology | Hematology Oncology
Advanced in Acute Megakaryoblastic Leukemia
Dr. Divaya Bhutani
Hematology | Oncology | Hematology Oncology

Trustees Of Columbia University In The City Of New York

161 Fort Washington Ave, 
New York, NY 
 (5.3 miles away)
212-305-3870
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Divaya Bhutani is a Hematologist and an Oncologist in New York, New York. Dr. Bhutani is rated as a Distinguished provider by MediFind in the treatment of Acute Megakaryoblastic Leukemia. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Primary Amyloidosis, Bone Marrow Transplant, and Bone Marrow Aspiration.

Advanced in Acute Megakaryoblastic Leukemia
Dr. Pritish K. Bhattacharyya
Hematology
Advanced in Acute Megakaryoblastic Leukemia
Dr. Pritish K. Bhattacharyya
Hematology

Morristown Pathology Associates PA

97 W Pkwy, 
Pompton Plains, NJ 
 (22.8 miles away)
973-831-5000
Languages Spoken:
English

Pritish Bhattacharyya is a Hematologist in Pompton Plains, New Jersey. Dr. Bhattacharyya is rated as an Advanced provider by MediFind in the treatment of Acute Megakaryoblastic Leukemia. His top areas of expertise are Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), and Acute Myeloblastic Leukemia with Maturation.

Experienced in Acute Megakaryoblastic Leukemia
Dr. Karen P. Seiter
Hematology
Experienced in Acute Megakaryoblastic Leukemia
Dr. Karen P. Seiter
Hematology

Westchester Medical Center Advanced Physician Services PC

100 Woods Rd, 
Valhalla, NY 
 (23.7 miles away)
914-490-7000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Karen Seiter is a Hematologist in Valhalla, New York. Dr. Seiter is rated as a Distinguished provider by MediFind in the treatment of Acute Megakaryoblastic Leukemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rampal's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 18 Advanced Conditions
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile